Search results for: Health Care Systems

Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing

11 May 2018

…that the price of a medicine should be linked in some way to the value it generates for patients and the health system is generally accepted. Yet, how can this…

A Critique of Hill et al. (2018) on Estimated Costs of Production for the WHO Essential Medicines List

19 May 2018

…reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors argue for “greater transparency…

Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C

26 July 2018

…impact of (i) incentives for R&D based on providing intellectual property (IP) rights protection; (ii) market competition; and (iii) other factors, including healthcare policies, on access to DAAs in Europe. …

Cookie Policy

Cookies are small data files transferred to your computer’s hard drive through your web browser to enable our systems to recognise your browser and to provide us with details of…

Shalu Jain

29 June 2023

…of Health Research (DHR), MOHFW, New Delhi, India as Scientist-C and played a key role in establishing Health Technology Assessment in India (HTAIn), a unit within the health ministry to…

Charlotte Ashton-Khan

1 August 2022

…including the UN, WHO and World Economic Forum, Charlotte is interested in maximising the impact of health economic research to build alliances that create a thriving ecosystem benefiting health systems…

Making Outcome-Based Payment a Reality in the NHS

2 January 2019

…Manchester Health and Social Care Partnership (GMHSCP). Please cite this report as: Cole, A., Cubi-Molla, P., Pollard, J., Sim, D., Sullivan, R., Sussex, J. and Lorgelly, P., 2019. Making Outcome-Based…

Pharmaceuticals in seven nations

1 May 1985

…becoming increasingly important to the economic prosperity of the advanced nations of the world.1 These industries need political understanding if they are to make their full contribution to the health…

Time to Tackle the Challenges around Combination Therapies for Cancer

29 March 2021

…paradigms (such as treatment durations and stopping rules that optimise health benefits and minimise adverse effects and costs). This is important but challenging. Significant progress seems unlikely in the short…